Equity in Access Research Grants

Equity in Access Research Grants

Status: ACTIVE
Funder: Leukemia & Lymphoma Society
Amount: Up to US $2,500,000
Last Updated: May 31, 2025

Summary

The Leukemia & Lymphoma Society's Equity in Access Research Grants aim to enhance equitable access to care for blood cancer patients and survivors. This program funds research to identify effective interventions that increase participation in clinical trials among underrepresented groups. Projects can receive up to $500,000 annually for a maximum of five years, with a total budget cap of $2.5 million. The initiative seeks to address systemic barriers that hinder clinical trial enrollment and improve healthcare access.

Overview

The Leukemia & Lymphoma Society’s (LLS) Equity in Access Research Program was created to help ensure more equitable access to care for blood cancer patients and survivors. Through this program, LLS aims to generate new evidence that can guide policy reform and changes in healthcare practice, in order to mitigate the impact of social, economic and environmental disadvantages and reduce barriers to care. Informed by a systematic review of the literature, the purpose of this Request for Proposals (RFP) is to fund research studies that will increase our understanding of effective interventions for increasing accrual to therapeutic cancer clinical trials, particularly among underrepresented populations. Specifically, we seek proposals that will implement and evaluate interventions designed to a) mitigate multilevel barriers to therapeutic clinical trial accrual for underrepresented groups and b) quantitatively measure the impact of these interventions on patient accrual. We are particularly interested in proposals that address systemic, institutional, and clinician-related barriers that impede clinical trial participation. Funding Available Maximum project period is 5 years, and the maximum funding amount per year is $500,000.Total budget, including indirect costs, should not exceed $2.5 million for a 5-year project period.Indirect costs are limited to 11.1% of the total direct costs during the Research Funding Term. Applicants should request the amount of funding they will need to complete the proposed research and disseminate findings. The review process will include an evaluation of the appropriateness of the funding request in light of study aims and methods to achieve the aims.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.